Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Virological response and antiviral resistance mutations in chronic hepatitis B subjects experiencing entecavir therapy: an Indian subcontinent perspective.

Ismail AM, Sharma OP, Kumar MS, Eapen CE, Kannangai R, Abraham P.

Antiviral Res. 2013 May;98(2):209-16. doi: 10.1016/j.antiviral.2013.02.012. Epub 2013 Feb 26.

PMID:
23485939
2.

Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.

Zhang Y, He S, Li QL, Guo JJ.

Virus Res. 2013 Nov 6;177(2):156-62. doi: 10.1016/j.virusres.2013.08.003. Epub 2013 Aug 19.

PMID:
23968804
3.

Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.

Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL.

Am J Gastroenterol. 2011 Jul;106(7):1264-71. doi: 10.1038/ajg.2011.45. Epub 2011 Mar 1.

PMID:
21364549
4.

Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy.

Liu F, Chen L, Yu DM, Deng L, Chen R, Jiang Y, Chen L, Huang SY, Yu JL, Gong QM, Zhang XX.

Gut. 2011 Sep;60(9):1269-77. doi: 10.1136/gut.2010.226225. Epub 2011 Feb 2.

PMID:
21292683
5.

Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.

Wong GL, Wong VW, Chan HY, Tse PC, Wong J, Chim AM, Yiu KK, Chu SH, Chan HL.

Aliment Pharmacol Ther. 2012 Jun;35(11):1326-35. doi: 10.1111/j.1365-2036.2012.05098.x. Epub 2012 Apr 16.

6.

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.

Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H.

J Hepatol. 2012 Sep;57(3):508-14. doi: 10.1016/j.jhep.2012.04.037. Epub 2012 May 30.

PMID:
22659518
8.

Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.

Yang JX, Liu BM, Li XG, Yan CH, Xu J, Sun XW, Wang YH, Jiao XJ, Yan L, Dong JP, Hou CS, Abuduheilili X, Li T, Zhuang H.

Antivir Ther. 2010;15(8):1171-8. doi: 10.3851/IMP1677.

PMID:
21149924
9.

Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.

Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bömmel F, Hansen BE, Wedemeyer H, Janssen HL; VIRGIL Surveillance Study Group.

J Hepatol. 2010 Apr;52(4):493-500. doi: 10.1016/j.jhep.2010.01.012. Epub 2010 Feb 4.

PMID:
20185191
10.

Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine.

Lo AO, Wong VW, Wong GL, Chan HY, Cheung CM, Chan HL.

Antivir Ther. 2013;18(5):671-9. doi: 10.3851/IMP2526. Epub 2013 Mar 5.

PMID:
23462214
11.

Complexity and diversity of hepatitis B virus quasispecies: correlation with long-term entecavir antiviral efficacy.

Tong J, Li QL, Huang AL, Guo JJ.

Antiviral Res. 2013 Sep;99(3):312-7. doi: 10.1016/j.antiviral.2013.06.020. Epub 2013 Jul 4.

PMID:
23832087
12.

HBV mutations associated with lamivudine therapy.

Lapiński TW, Parfieniuk-Kowerda A, Trzos A, Jaroszewicz J, Kowalczuk O, Nikliński J, Flisiak R.

Przegl Epidemiol. 2013;67(4):611-6, 705-8. English, Polish.

13.

Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?

Lee GH, Aung MO, Dan YY, Lee YM, Mak B, Low HC, Lim K, Thwin MA, Tan PS, Lim SG.

J Med Virol. 2013 Jan;85(1):26-33. doi: 10.1002/jmv.23392. Epub 2012 Sep 28.

PMID:
23023992
14.

Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.

Pan CQ, Hu KQ, Yu AS, Chen W, Bunchorntavakul C, Reddy KR.

J Viral Hepat. 2012 Mar;19(3):213-9. doi: 10.1111/j.1365-2893.2011.01533.x. Epub 2011 Oct 17.

PMID:
22329376
15.

Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.

Ong A, Wong VW, Wong GL, Chan HY, Tse CH, Chan HL.

Aliment Pharmacol Ther. 2011 Oct;34(8):972-81. doi: 10.1111/j.1365-2036.2011.04833.x. Epub 2011 Aug 24.

16.

Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.

Kwon SY, Park YK, Ahn SH, Cho ES, Choe WH, Lee CH, Kim BK, Ko SY, Choi HS, Park ES, Shin GC, Kim KH.

J Virol. 2010 May;84(9):4494-503. doi: 10.1128/JVI.02066-09. Epub 2010 Feb 17.

17.

Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.

Salpini R, Alteri C, Cento V, Pollicita M, Micheli V, Gubertini G, De Sanctis GM, Visca M, Romano S, Sarrecchia C, Andreoni M, Angelico M, Parruti G, Svicher V, Perno CF.

J Med Virol. 2013 Jun;85(6):996-1004. doi: 10.1002/jmv.23567.

PMID:
23588725
18.

[Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].

Sayan M, Hülagü S, Akhan SC, Sentürk O, Meriç M, Cekmen M.

Mikrobiyol Bul. 2009 Jul;43(3):425-32. Turkish.

PMID:
19795617
19.

Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.

Karatayli E, Karatayli SC, Cinar K, Gokahmetoglu S, Güven K, Idilman R, Yurdaydin C, Bozdayi AM.

J Clin Virol. 2012 Feb;53(2):130-4. doi: 10.1016/j.jcv.2011.10.011. Epub 2011 Nov 9.

PMID:
22078148
20.

Supplemental Content

Support Center